of paclitaxel was nearly negligible at 6 h In case of Taxol®, and it was readily
clean and uptake by the liver, spleen and lung. The plasma concentration was sustained
for up to 24 h ,when paclitaxel was encapsulated in liposomes,
compare to conventional liposomes, the plasma concentration level was greater
in PEGylated liposomes after conducting pharmacokinetic test in rats.
of 6 and 24 h of pharmacokinetic study of the Taxol® in Tumor tissue, efficiency of
PEGylated liposomes show significantly higher than that of conventional
liposomes and also PEGylated paclitaxel liposome concentration was more in
tumor than in spleen, lung, heart, kidney and brain tissues from 6h. from these
results we can judge the localization effect PEGylated liposomes in tumor
like that slow discharge and long-circulating period of PEGylated liposomes
could offer sufficient chance for paclitaxel to be achieved at the tumor site
through the EPR effect and preserve the effective therapeutic concentration for
a long period of time through the depot effect.
these results indicate that our PEGylated liposomal formulation purposely
increased the antitumor effectiveness while weakening the potential alternative
of tumor growth:
the paclitaxel loaded classical liposomes and PEGylated liposomes have been
pretty stored inside the tumor tissues of MDA-MB-231 human breast most cancers
xenograft model, the tumor growth inhibition impact was in addition
anticipated. The examine at the manipulate (saline) group stopped at the thirty
fifth day motive is that the tumor capacity was extremely enlarged (about 2000
mm3), while other agencies lasted till the sixtieth day.
The PEGylated liposomes inhibited tumor boom most
successfully, accompanied by way of the traditional liposomes and Taxol® (p
< zero.05). This improved anti-tumor pastime of the PEGylated liposomes may be clarified by means of the expanded nearby attention of pacltiaxel near the tumor thru EPR effect.